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Introduction: The recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) is undergoing
clinical trials for prophylaxis and on-demand treatment of haemophilia B patients. The aim of this study was
to investigate the pharmacokinetics, whole-body and knee joint distribution of rIX-FP following intravenous ad-
ministration to rats, compared with a marketed, non-fused rFIX and recombinant human albumin.
Material and Methods: [3H]-rIX-FP, [3H]-rFIX or [3H]-albumin were administered to rats followed by quantitative
whole-body autoradiography over 24 or 240 hours, and the tissue distribution as well as elimination of radioac-
tivity were measured.
Results: Elimination of all radioactivity derived from the three proteins was shown to occur primarily via the
urine. The tissue distribution of [3H]-rIX-FP and [3H]-rFIX (but not of [3H]-albumin) was comparable, both pen-
etrating predominantly into bone, and well-perfused tissues, suggesting that the rIX moiety determines the dis-
tribution pattern of rIX-FP,while the albuminmoity is responsible for the prolonged plasma and tissue retention.
Detailed knee-joint analysis indicated rapid presence of [3H]-rIX-FP and [3H]-rFIX in synovial and mineralised
bone tissue, mostly localised to the zone of calciﬁed cartilage. Longest retention times were observed in the
bonemarrow and the endosteum of long bones. Intriguingly, [3H]-rIX-FP- and [3H]-albumin-derived radioactive
signals were detectable up to 240 hours, while [3H]-rFIX-derived radioactivity rapidly declined after 1 hour post-
dosing correlating to the extended plasma half-life of [3H]-rIX-FP.
Conclusion: The prolonged plasma and tissue retention of rIX-FP achieved by albumin fusion may allow a reduc-
tion in dosing frequency leading to increased therapeutic compliance and convenience.© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Factor IX (FIX) is the zymogen of a serine protease that circulates in
plasma at an average concentration of 5 μg/ml [1]. Activated FIX (FIXa)
is an integral part of the tenase enzyme complex activating factor X, ul-
timately leading to blood coagulation [2,3]. FIX-replacement therapy,
using recombinant (rFIX) or plasma-derived (pdFIX) FIX is a safe and
efﬁcacious treatment approach to reduce bleeding rates among
haemophilia B patients, while limiting haemarthrosis and arthropathyecombinant FIX; pdFIX, plasma-
factor IX with albumin; QWBA,
ntillation counting; LMW, low-
Fc-receptor.
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is an open access article under the C(potential causes of disability) [4]. Unfortunately, the relatively short
terminal half-life of FIX of approximately 18–34 hours, necessitates fre-
quent infusions every 2 or 3 days tomaintain FIX clotting activity above
1% and to prevent spontaneous bleeding [5,6].
To improve therapeutic compliance and convenience, a novel re-
combinant fusion protein linking coagulation factor IX with albumin
via a cleavable peptide linker (rIX-FP) has been designed to prolong
the circulation time of FIX signiﬁcantly; thus, improving its pharmaco-
kinetic proﬁle while maintaining its efﬁcacy [7–9]. Understanding the
tissue distribution of this novel coagulation factor construct is impor-
tant to ensure that it reaches those areas necessary for maximum
haemostatic efﬁcacy. However, there is limited information available
on the tissue distribution of FIX (rFIX/pdFIX) following intravenous ad-
ministration and how fusion with albumin, as in the case of rIX-FP, may
affect it. Therefore, this study aimed to investigate the pharmacokinet-
ics and whole-body distribution of rIX-FP following intravenous
administration of radiolabeled rIX-FP to rats, compared with a
marketed, non-fused rFIX and recombinant human albumin, with par-
ticular focus on the bone–joint distribution proﬁle.C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Recovery* of radioactivity in rat plasma, urine, and faeces following a single intravenous
administration of [3H]-rIX-FP, [3H]-rFIX, or [3H]-albumin.
Sample Time (hours) [3H]-rIX-FP [3H]-rFIX [3H]-albumin
Plasma 0.25 100 91.7 100
1 100 86.3 100
3 100 68.6 98.3
8 100 – 96.3
24 73.0 44.3 97.4
72 60.7 – 79.3
120 0.97 – 73.6
240 0.29 – BLQ
Urine 0–8 13.5 11.7 10.7
8–24 26.4 39.3† 36.7
24–48 16.9 – 28.7
48–240 16.1 – 37.2
Subtotal 72.9 51.0 113.3
Faeces 0–24 0.9 8.9 3.7
24–48 0.8 – 1.9
48–240 2.6 – 6.9
Subtotal 4.3 8.9 12.5
Cage wash Subtotal 3.7 2.9 0.7
Total 80.8 62.8 126.5
*Expressed as % of overall radioactivity administered. †Sample collection for rFIX was
0−6 hours. BLQ, below limit of quantiﬁcation. rFIX, recombinant factor IX; rIX-FP,
recombinant fusion protein linking coagulation factor IX with albumin; –, no mea-
surement for that time point.
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Radiolabelling and Characterisation of rIX-FP and rFIX
rIX-FP (CSL Behring GmbH, Germany), rFIX (BeneFIX®, Pﬁzer
Pharma GmbH, Berlin, Germany) or albumin (Recombumin®,
Novozymes Biopharma, Bagsvaerd, Denmark) were radiolabeled
with N-succinimidyl-[2,3-3H]-propionate (Quotient Bioresearch,
Cardiff, UK), using the method described by Müller [10].
Treatments
Male Sprague-Dawley rats (Charles River, UK) received a slow bolus
radioactive dose of 11−16 MBq/kg (320−420 μCi/kg) [3H]-rIX-FP,
[3H]-rFIX, or [3H]-albumin. All animals received care in compliance
with the European Convention on Animal Care and the study was ap-
proved by the local Ethics Committee.
Plasma Analysis
Following intravenous dosing, blood samples (~5−10ml) were col-
lected into individual heparinised containers using cardiac puncture
under anaesthesia (isoﬂuorane) at the following post-dose time points
(one animal/time point): 0.25, 1, 3, 8, 24, 72, 120, and 240 hours for
[3H]-rIX-FP- and [3H]-albumin-treated animals, and based on previous
pharmacokinetic data, 0.25, 1, 3, and 24 hours for [3H]-rFIX-treated an-
imals. The whole-blood samples were centrifuged and the resultant
plasma harvested.
Excretion Balance
After dosing, animals selected for the ﬁnal autoradiography time
point (240 hours for [3H]-rIX-FP or [3H]-albumin, and 24 hours for
[3H]-rFIX) were returned to glass metabolism cages for separate urine
(at 0−8 hours, 8−24 hours and 24-hour intervals thereafter) and
faeces (at 24-hour intervals) collection. At the end of the observation
period, themetabolismcageswere rinsedwithwater followed bymeth-
anol, and the washings collected for quantitative radiochemical
analysis.
Quantitative Whole-body Autoradiography (QWBA)
QWBA analysis was performed based on the technique of
Ullberg [11] at time points up to 24 ([3H]-rFIX) or 240 hours
([3H]-rIX-FP, [3H]-albumin). Sagittal sections of the body were
assessed at up to ﬁve different levels: Level 1, exorbital lachrymal
gland; Level 2, intra-orbital lachrymal gland; Level 3, harderian
gland/adrenal gland; Level 4, thyroid gland; and Level 5, brain
and spinal cord. A calibration curve was created via SeeScan using
data from the 3H-blood standards from which tissue concentrations of
radioactivity were determined (nCi/g). Percentage total dose/tissue
was also determined. Additionally, one hind limb from each animal
was used for separate sectioning and a more detailed analysis of the
knee joint.
Quantitative Radiochemical and Chromatographic Analysis
Liquid scintillation counting (LSC) was used to determine the radio-
activity level (disintegrations/minute) of the dose formulation, plasma,
urine, faeces, and cage wash using a Packard 2300TR liquid scintillation
analyser (PerkinElmer, Waltham, MA, USA) with automatic external
standard quench correction and Ultima Gold XR scintillation ﬂuid
(PerkinElmer). Proportions of radioactivity in puriﬁed 3H-labeled pro-
tein solutions, plasma and urine samples were determined by high-
performance liquid chromatography (HPLC; Agilent 1100 HPLC system
with ultraviolet detection at 280 nm) using a Phenomenex BIOSEP SEC2000 size exclusion column (300 × 7.8 mm; mobile phase 100 mM so-
dium phosphate or 0.1 M phosphate buffer for protein solutions and
body ﬂuids, respectively). FIX antigen levelswere alsomeasured to con-
ﬁrm the presence of rIX-FP in tissues.Results
Characterisation of [3H]-rIX-FP and [3H]-rFIX Preparations
Radiochemical purity of the [3H]-rIX-FP, [3H]-rFIX, and [3H]-albumin
formulations was N 90% as determined by HPLC analysis and shown in
Fig. S1a i, ii, and iii, respectively. Assessment of the biological activity
conﬁrmed that 100% of rIX-FP speciﬁc activity was maintained follow-
ing [3H]-labelling based on measurements of FIX activity (Fig. S1b).Analysis of Circulating Radioactivity and Pharmacokinetics
Plasma analysis conﬁrmed the mean dose levels of ~400 μCi/kg in
each treatment group: [3H]-rIX-FP, 409 μCi/kg; [3H]-rFIX, 425 μCi/kg;
and [3H]-albumin, 382 μCi/kg. For direct comparisons of FIX products,
radioactive dose level differences were considered when interpreting
the plasma and tissue concentration data. Plasma radioactivity levels
and representative radiochromatograms of [3H]-rIX-FP, [3H]-rFIX, and
[3H]-albumin are shown in Table S1 and Fig. S2 (a-c), respectively.
Levels of intact protein recovered in plasma are shown in Table 1 and
Fig. 1a.[3H]-rIX-FP
Unchanged [3H]-rIX-FP (peak at ~7 minutes) was the major compo-
nent in plasma, accounting for ~100% of all radioactivity up to 8 hours
post-dosing (see Table 1). At 24 hours, this declined to 73.0%,with the re-
maining radioactivity composed of two peaks that co-chromatographed
with albumin (at ~8.5 minutes) and a low-molecular-weight (LMW)
component (at 13.4 minutes), and represented 16.5% and 3.7% of the
total radioactivity, respectively (Table S1 and Fig. S2a). [3H]-rIX-FP levels
continued to decline with time, with b 1.0% at 120 hours and almost un-
detectable at 240 hours (Table 1).
Fig. 1. Concentration of radioactivity in plasma (a), kidney (b), and liver (c) at
0.25–240 hours following intravenous administration of [3H]-rIX-FP, [3H]-rFIX, or
[3H]-albumin to rats. rFIX, recombinant factor IX; rIX-FP, recombinant fusion protein
linking coagulation factor IX with albumin.
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240 hours ([3H]-rIX-FP; [3H]-albumin) or 24 hours ([3H]-rFIX) indicat-
ed that [3H]-rIX-FP was cleared slowly with a terminal half-life of
20.4 hours and a clearance of 2.1 ml/hour (Fig. 1a).
[3H]-rFIX
Unchanged [3H]-rFIX in plasma at 15 minutes post-dose accounted
for 91.7% of the total radioactivity (Table 1). This declined to 44.3% at
24 hours post-dose, with the majority of the remaining radioactivity
(10.5%) associated with a LMW component (Table S1 and Fig. S2b).
[3H]-rFIX had a shorter half-life of 6.1 hours and a faster clearance of
15.4 ml/hour compared with [3H]-rIX-FP (Fig. 1a).
[3H]-albumin
[3H]-albuminwas detected in plasmaas a single peak at ~8.5 minutes
(Fig. S2c). Up to 3 hours, all radioactivity measured was attributed to in-
tact protein (Table 1). From 8 to 240 hours, a second LMW peak ap-
peared at 13 minutes (Table S1 and Fig. S2c). Similarly to [3H]-rIX-FP,
levels of [3H]-albumin dropped to undetectable levels after 240 hours
(Table 1). [3H]-albumin had a half-life of 25.0 hours and a clearance of
0.7 ml/hour (Fig. 1a).Excretion Balance
[3H]-rIX-FP
Urinary excretion accounted for 72.9% of the [3H]-rIX-FP dose elim-
inated up to 240 hours (Table 1). [3H]-rIX-FP was eliminated in the
form of a non-volatile LMW component, in the absence of any high-
molecular-weight components (Fig. S2d). Faecal elimination accounted
for 4.3% of the dose (Table 1). Overall, 80.9% of the total administered
dose was recovered by 240 hours (Table 1).
[3H]-rFIX
Up to 24 hours post-dose of [3H]-rFIX, the majority of radioactivity
was recovered in the urine (51.0%) in the form of a LMW component
(Table 1 and Fig. S2e); 8.9%was eliminated via the faecal route (Table 1).
[3H]-albumin
Urinary excretion accounted for almost half (47.5%) of the [3H]-
albumin elimination during the ﬁrst 24 hours, with a total of
113.4% being recovered by 240 hours in the form of a LMW compo-
nent (Table 1 and Fig. S2f); faecal excretion represented 12.5% of
the dose (Table 1).
Tissue Distribution
Tissue Concentrations and Kinetics
[3H]-rIX-FP. Fig. 2 and Fig. S3 display the quantitativewhole boday auto-
radiography images obtained at two different sectioning levels at 0.25
to 24 hours post [3H]-rlX-FP dosing. Image analysis conﬁrmed that
peak [3H]-rlX-FP radioactivity levels were detected in the adrenal
gland, followed by the kidney (particularly the medullary region),
bone endosteum, spleen, lung, liver, and bonemarrow (maximum con-
centrations of 2,020.0–7,040.0 nCi/g). High levels were also detected in
other well-vascularised tissues such as the mucosa of the intestines,
myocardium, and periodontal membrane (with maximum concentra-
tions of 1,140.0−1,980.0 nCi/g), and the bulbo-urethral, pituitary
glands, epididymis, and testes (maximum concentrations of 720.0−
2,110.0 nCi/g).
Comparison of the tissue radioactivity over time indicated that peak
radioactivity concentrations generally occurred at 3−8 hours post-
dose, except in the adrenal gland and spleen, where they occurred at
0.25 hours and declined thereafter (Fig. 2 and Fig. S3). Levels in spleen,
lung, and liver remained approximately constant at 0.25–8 hours post-
dose. The longest radioactivity retention was in bone endosteum. Com-
parable levels were only detected up to 24 hours in other tissues
(Fig. 2). Levels in the kidney, whose concentrations over time are
illustrated in Fig. 1b, increased up to 8 hours post-dose, whereas con-
centrations in the liver remained steady up to 3 hours and decreased
thereafter (Fig. 1c).
The timecourse of radioactivity concentrations observed along
the gastrointestinal (GI) tract is listed in Table S2. As can be seen,
peak concentrations of [3H]-rlX-FP in the small (350.0 nCi/g) and
large (69.2 nCi/g) intestines occurred at 3−8 hours, whereas the
caecum level remained below the limit of quantiﬁcation, indicating
reabsorption or re-use of radiolabeledmaterial during its GI passage.
In addition to autoradiographic tissue analysis, FIX antigen
levels were determined in homogenized tissue samples following
intravenous dosing of rIX-FP to rats. Preliminary data could con-
ﬁrm that the radioactive signals corresponded to the rIX-FP
protein (Fig. S4).
[3H]-rFIX. The pattern of tissue distribution of [3H]-rFIX was identical to
that of [3H]-rlX-FP as can seen in Fig. 3 displaying QWBA images obtain-
ed at 0.25 hours and 24 hours post dosing (maximum concentrations of
1,630.0−6,240 nCi/g). At this later timepoint of 24 hours, highest levels
occurred in the bone endosteum.
Fig. 2. Quantitative whole-body autoradiography images obtained at 0.25–240 hours fol-
lowing a single intravenous administration of [3H]-rlX-FP to male albino rats (Level 3). h,
hours; rFIX, recombinant factor IX; rIX-FP, recombinant fusion protein linking coagulation
factor IX with albumin.
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those of the liver by N 2-fold, conﬁrming the kidney as the primary
excretion organ of [3H]-rFlX (Fig. 1b,c). Additionally, concentra-
tions up to 5,870.0 nCi/g were detected in bladder contents, whileconcentrations within the small intestine, large intestine, and caecum
contents remained b 178.0 nCi/g. However, in contrast to [3H]-rIX-FP
treatment, radioactivity was detectable within caecum contents,
peaking at 128.0 nCi/g at 24 hours (Table S2).
[3H]-albumin. In contrast to [3H]-rIX-FP and [3H]-rFlX, the highest tis-
sue concentrations following [3H]-albumin administration occurred
in the periodontal membrane, tooth pulp, and bulbo-urethral gland
(maximum levels 4,070.0−4,650.0 nCi/g); followed by the lungs,
kidney, and bone endosteum (2,340.0−3,400.0 nCi/g) (Fig. 3).
High radioactivity concentrations were also observed in other highly
vascularised tissues [nasal and caecum mucosa, myocardium, stom-
ach wall, aorta (1,230.0−1,930.0 nCi/g)], as well as the epididymis,
testes, lymph nodes, harderian glands, and bone periosteum
(1,040.0−1,530.0 nCi/g).
Following [3H]-albumin treatment, maximum concentrations
were generally reached at 3 hours post-dose. By 72 hours, radioac-
tivity concentrations of all tissues had declined markedly with the
longest tissue retention seen for the bone periosteum at 240 hours
(data not shown). High levels of radioactivity were detected in the
kidney, particularly the medulla region, which reached peak levels
after 3 hours, slightly earlier than that of [3H]-rIX-FP, but later
than that of [3H]-rFIX (Fig. 1b). Also, in contrast to [3H]-rIX-FP and
[3H]-rFIX, concentrations of [3H]-albumin-derived radioactivity in
the liver remained b179.0 nCi/g, much lower than levels with
[3H]-rIX-FP or [3H]-rFIX (Fig. 1c). Concentrations within small in-
testine contents reached a maximum of 492.0 nCi/g at 1 hour
post-dose. In comparison, large intestine and caecum contents
displayed maximum concentrations of only 52.3 and 96.7 nCi/g, re-
spectively, again indicating some reabsorption of radioactivity
(Table S2).
Total Dose Per Tissue
[3H]-rIX-FP. In addition to the tissue concentrations of radioactivity, the
total dose of radioactivity per tissue was determined and indicated that
the liver received the highest total dose of [3H]-rlX-FP, followed bymus-
cle, kidney, lungs, and bone marrow (Fig. 4a).
[3H]-rFIX. The pattern of the total radioactivity per tissue derived from
[3H]-rFIXwas similar to that seen after [3H]-rIX-FP dosing (Fig. 4b). How-
ever, at 24 hours post-dose, the levels of [3H]-rFIX-derived radioactivity
inmost tissues had declined to levels below those seenwith [3H]-rIX-FP.
[3H]-albumin.Muscle tissue received the highest total dose of [3H]-albu-
min (Fig. 4c). Overall, 73.3% of the dose could be detectedwithinmuscle
at 8 hours. Levels in muscle, intestinal mucosa, skin, and lymph nodes
were higher at 24 than 0.25 hours.
Knee-joint Distribution
[3H]-rlX-FP. Autoradiography images of the knee joint area analysed
seperately are compared in Fig. 5. Fig. S5 includes the corresponding
radioactivity concentrations determined for knee joint tissues. The
data show that the highest radioactivity concentrations occurred
in the calciﬁed cartilage of the growth plate (5,190.0 nCi/g),
followed by the bone endosteum (3,440.0 nCi/g), bone marrow
(2,200.0 nCi/g), synovial space (709.0 nCi/g) and bone periosteum
(515.0 nCi/g). Compact bone of the femur, ﬁbula, and tibia, epiphys-
ial plate and meniscus displayed low levels throughout. As can be
seen in Fig. 5, maximum concentrations occurred at 8 hours, except
in the periosteum, which peaked at 3 hours, and in the bone endos-
teum, which peaked at 120 hours and exhibited the longest reten-
tion of radioactivity.
Fig. 3.Quantitativewhole-body autoradiography image obtained at 0.25 (left panel) or 24 hours (right panel) after single intravenous administration of [3H]-rlX-FP, [3H]-rFlX, or [3H]-rFlX
to rats. rFIX, recombinant factor IX; rIX-FP, recombinant fusion protein linking coagulation factor IX with albumin.
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served at ~1 hour post-dose, with a similar overall distribution pro-
ﬁle to that of [3H]-rlX-FP (Fig. 5 and Fig. S5). Highest concentrations
also occurred in the calciﬁed cartilage of the growth plate andFig. 4. Tissue distribution of radioactivity (average of % dose per tissue) at 0.25 and 24 hours follow
Tissue distribution cut-off: minimum of 0.5% per tissue at any given time point. rFIX, recombinaendosteum, and low levels within compact bone or the synovial
space. However, peak levels in calciﬁed cartilage, endosteum, bone
marrow, and periosteum (413.0−3,320.0 nCi/g), were below those
seen following [3H]-rlX-FP.ing intravenous administration of [3H]-rIX-FP (a), [3H]-rFIX (b), or [3H]-albumin (c) to rats.
nt factor IX; rIX-FP, recombinant fusion protein linking coagulation factor IX with albumin.
Fig. 5.Quantitative whole-body autoradiography images of knee-joint region following a single intravenous administration of [3H]-rIX-FP, [3H]-rFIX, or [3H]-albumin to rats. rFIX, recom-
binant factor IX; rIX-FP, recombinant fusion protein linking coagulation factor IX with albumin.
905E. Herzog et al. / Thrombosis Research 133 (2014) 900–907[3H]-albumin. Following [3H]-albumin dosing, concentrations of
radioactivity within the knee joint tissues were lower compared
with [3H]-rlX-FP and maximum levels were observed in the bone
periosteum (2,570.0 nCi/g), with peak levels at 3 hours post-dose,
followed by the calciﬁed cartilage (1,590.0 nCi/g), bone endosteum
(814.0 nCi/g), and bone marrow (576.0 nCi/g), which peaked at
0.25 hours post-dosing (Fig. 5and Fig. S5).
Discussion
This study aimed to deﬁne further the in vivo characteristics of rIX-
FP, which is currently undergoing clinical trials. Direct comparison
with a currently available rFIX product, which has been approved for
clinical use since 1997 [12,13], enabled an investigation of the inﬂuence
of albumin fusion on the tissue distribution proﬁle of rFIX.
Plasma Kinetics and Elimination
Importantly, [3H]-rIX-FP had a prolonged plasma terminal half-life
compared with [3H]-rFIX (20.4 versus 6.1 hours). This half-life exten-
sion is a key feature of rIX-FP and results from the fusion with albuminand agreeswith studies byMetzner et al. [7] andNolte et al. [8] showing
an increase in the terminal half-life over rFIX by ~2.3- to 5.0-fold follow-
ing albumin fusion across animal species. The former study furthermore
conﬁrms that the [3H]-labelling procedure does not affect the
pharmacokinetic characteristics of rIX-FP or rFIX as equal values for
the terminal half-lives in rats were reported as seen in the present
study (i.e. 24.1 versus 5.1 hours) [7].
The main elimination route for [3H]-rIX-FP, [3H]-rFIX, and [3H]-
albumin was renal, as indicated by the urinary versus faecal excre-
tion proﬁle and radioactivity concentrations within the kidney, and
as described by previous studies of rFIX [14,15]. The majority of the
radioactivity excreted in urine was in the form of a non-volatile
LMW component, while intact rIX-FP, rFIX, or albumin proteins
were absent, suggesting endocytosis of the proteins and subsequent
degradation by lysosomal proteases, as described for other proteins
[16,17].
Following administration of [3H]-rIX-FP and [3H]-rFIX, but not [3H]-
albumin, substantial radioactivity levels were detected within the liver,
accounting for the highest total dose/tissue, indicating an important
role of the liver during FIX metabolism and subsequent distribution.
One explanation may be the interaction of FIX with thrombin-binding
906 E. Herzog et al. / Thrombosis Research 133 (2014) 900–907sites, such as the serine protease inhibitor antithrombin III (ATIII), on
endothelial cells of the liver [14,15] or speciﬁc low-density lipoprotein
elimination pathways [18,19].
Similarly, following intravenous administration of [125I]-FIXa or
[131I]-rFIX to rodents, 80− 90% of the radioactivity was recovered in
the liver at 2− 5 minutes post-dose [14,15]. The same studies also re-
ported accumulation of radioactivity in the kidneys.
The radioactivity levels in both the liver and kidney rapidly de-
clined after [3H]-rFIX dosing, which agrees with studies that re-
ported no accumulation of mouse rFIX in these organs [20].
Similarly, there was no retention or accumulation of radioactivity
following [3H]-rIX-FP or [3H]-albumin administration, even though
the presence of albumin appeared to result in a delayed decrease
in kidney and liver concentrations, with peak levels occurring at
3–8 hours.
Interestingly, a potential reabsorption of radioactive components
during their passage through the gastrointestinal tract was observed,
as indicated by the radioactivity levels in the small intestine and caecum
contents, together with the high radioactivity levels in the intestinal
mucosa, which would indicate enterohepatic circulation of [3H]-rIX-FP
and [3H]-rFIX or their degradation products.
Tissue Distribution
Albumin fusion did not affect the tissue distribution proﬁle of [3H]-
rIX-FP compared with [3H]-rFIX. However, while initial radioactivity
levels were comparable for both [3H]-rIX-FP and [3H]-rFIX, levels
of [3H]-rFIX declined much earlier, beginning 1 hour post-dose. In
contrast, signals of [3H]-rIX-FP were detectable until much later time
points: up to 240 hours in bone tissue, adrenal gland, kidney, and intes-
tinal mucosa. Although, at this time point, plasma radioactivity could
not be directly assigned to intact [3H]-rIX-FP protein, as the similarity
in the distinct pattern of tissue distribution to all earlier time points sug-
gests that the tissue concentration may still represent unchanged
protein. Similar to [3H]-rIX-FP, [3H]-albumin-derived radioactivity
was detectable up to 240 hours, indicating comparable tissue reten-
tion. However, in contrast to [3H]-rIX-FP and [3H]-rIX, [3H]-albumin
elicited a distinct tissue distribution pattern. Thus, it is concluded
that rFIX is the main determinant of the tissue distribution of rIX-
FP, whereas albumin fusion appears to determine its extended tissue
retention.
Similar to studies by Chang et al., no radioactivity was observed
in brain tissue [14], thereby limiting the prothrombotic risk associat-
ed with FIX within this tissue. Interestingly, initial distribution was
particularly high for the adrenal gland, which seemed to be a speciﬁc
property of [3H]-rIX-FP and [3H]-rFIX, as it was not observed for
[3H]-albumin. Glandular tissues (e.g., bulbo-urethral gland, epididy-
mis, pituitary gland, salivary gland, thyroid, prostate, lachrymal or
Harderian gland) showed elevated radioactivity levels following ad-
ministration of all three proteins.
The high levels of radioactivity observed in well-vascularised tis-
sues may be due to the high vascular concentrations of the test items
potentially resulting in increased tissue compartmentalisation, and
possibly incomplete perfusion of animals post-mortem. However,
some degree of tissue compartmentalisation is likely for the FIX pro-
teins studied. Several mechanisms have been proposed for the fate of
coagulation proteins upon intravenous administration. The interac-
tion of the FIX Gla domain with collagen IV on endothelial surfaces
has been shown to affect the rate of FIX clearance and endothelial se-
questration [21–23]. The endotheliummay represent a FIX reservoir,
protecting FIX from normal clearance mechanisms [24]; however,
conﬂicting evidence exists on FIX binding to endothelial cells follow-
ing systemic exposure [15,20].
Binding to the neonatal Fc-receptor (FcRn) may represent anoth-
er mechanism directly affecting the biodistribution of rIX-FP and al-
bumin, but not of rFIX [25–27], and underlying the prolongedbiological half-life of rIX-FP. However, translation of FcRn effects
from animal studies to humans is complicated due to species differ-
ences in FcRn binding [28,29]. In addition to FcRn, albumin interacts
with other receptors and extracellular matrix components, which
may affect the pharmacokinetics and biodistribution of the fused co-
agulation factor [30–33]. Further studies are warranted to investi-
gate the exact interaction between rIX-FP and the endothelial cell
lining to explore potential sequestration mechanisms to extravascu-
lar tissue.
In-depth analysis of the knee-joint distribution conﬁrmed the longest
retention period of [3H]-rFIX and [3H]-rIX-FPwithin themineralised bone
region, particularly the bone-formative areas [20]. Investigations from
Thomsen and co-workers suggested that only proteins containing the
Gla-domain are sequestered in bonevia binding to hydroxyapatite during
mineral maturation, with the bone compartment serving as a storage site
for these vitamin K-dependent clotting factors [34]. While rFIX seques-
tered in the bone disappeared by 24 hours post-dose, [3H]-rIX-FP could
be detected up to 120− 240 hours. This may be explained by the inter-
action of albumin with its receptors or other matrix components, such as
osteonectin [35]. As osteonectin is localised to mineralised bone trabecu-
lae and occurs at higher levels in thematrix than in bone cells, binding to
osteonectin may partly explain the observed bone distribution and
retention of rIX-FP. Furthermore, increased albumin permeability of the
blood− joint barrier has beendescribed for patientswith rheumatoid ar-
thritis [36], and in preclinical arthritis models [37]; thus, rIX-FP retention
could be related to preferential uptake of albumin. Follow-up studies are
required to conﬁrm the presence of intact rIX-FP within bone tissue and
further characterise the exact binding sites.
Overall, the present QWBA studies comparing the distribution and
elimination of [3H]-rIX-FP, [3H]-rFIX, and [3H]-albumin indicate that re-
combinant genetic fusion of rFIX to human albumin using a cleavable
linker does not affect the general tissue distribution proﬁle of rIX-FP
compared with rFIX. However, albumin fusion markedly extends the
circulatory half-life and tissue retention after intravenous administra-
tion. The prolonged tissue retention may be due to changes in speciﬁc
receptor-mediated mechanisms, or albumin-mediated increase in mo-
lecular volume andmasking of rFIX, rendering the protein less immuno-
genic and more resistant to proteases, ultimately resulting in retarded
clearance [38,39]. However, the exact mechanism would still need to
be elucidated and conﬁrmed.
It should be noted that the present study was conducted in healthy
rats which display normal FIX background levels in contrast to Hemo-
philia B patients. Future biodistribution studies using FIX-deﬁcient ani-
mal models may therefore further support the translation of animal
biodistribution data to human patients.
The favourable pharmacokinetic and pharmacodynamic proﬁle
of rIX-FP may directly translate into improved coagulation replace-
ment therapy with less frequent dosing required to maintain ap-
propriate FIX levels during prophylaxis, particularly within joint
tissue.
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